Pancreatic ductal adenocarcinoma (PDAC) and other carcinomas are hierarchically organized with cancer stem cells (CSC) residing at the top of the hierarchy where they drive tumor progression, metastasis and chemoresistance. Since CSC and non-CSC share an identical genetic background, we hypothesize that differences in epigenetics account for the striking functional differences between these two cell populations. Epigenetic mechanisms such as DNA methylation play an important role in maintaining pluripotency and regulating the differentiation of stem cells, but the role of DNA methylation in pancreatic CSC is obscure. In this study, we investigated the genome-wide DNA methylation profile of PDAC CSC and we determined the importance of DNMT methyltransferases for CSC maintenance and tumorigenicity. Using high-throughput methylation analysis, we discovered that sorted CSC have a higher level of DNA methylation, regardless of the heterogeneity or polyclonality of the CSC populations present in the tumors analyzed. Mechanistically, CSC expressed higher DNMT1 levels than non-CSC.
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INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) represents the 4 th most frequent cause of cancerrelated death due to its extreme lethality and current lack of effective treatments (1). As incidence and death rates continue to increase, pancreatic cancer is predicted to become the 2 nd most frequent cause of cancer-related death by 2030 (2) , making this disease a major unmet priority in public healthcare. While multiple subclonal populations of cancer cells coexist within each tumor and are assumed to drive tumor adaptation and therapeutic failure through Darwinian selection (3), convincing evidence now demonstrates that cancer heterogeneity is also driven by phenotypic and functional heterogeneity within each of these subclones, resulting in a hierarchical tumor organization (4) . At the apex of this hierarchy are populations of cancer stem cells (CSCs) capable of self-renewal and long-term in vivo tumorigenicity.
CSCs give rise to more differentiated progenies (non-CSCs), which, although sharing common mutation profiles, bear distinct and thus most likely epigenetically defined gene expression patterns (5, 6) .
Identifying the epigenetic mechanisms that are responsible for the acquisition and preservation of these distinct CSC features could open up possibilities for the development of new and more effective therapeutic strategies for PDAC. Unlike genetic mutations, epigenetic changes are transient and reversible, and as such, therapies that convert the epigenetic balance of CSCs towards that of non-CSCs could provide the basis for developing more effective treatment strategies for cancer patients (7) . Among the first epigenetic drugs proposed were inhibitors of DNA methylation, e.g. 5-azacytidine (5-aza-CR, azacitidine) and 5-aza-2′-deoxycytidine (5-aza-CdR, Decitabine), followed later by Zebularine, which all incorporate into DNA and form covalent irreversible complexes with DNA methyltransferases (DNMTs) (8) . These inhibitors have been shown to induce differentiation of cultured cancer cells (9) , but our knowledge about their effects on CSCs is still sparse. Moreover, to date only few studies have utilized the new DNA methylation inhibitor Zebularine, which can be administered orally and is less toxic (10) . Thus, we aimed to characterize the supposedly distinct methylation profile of primary pancreatic CSCs and subsequently studied the effects of genetic or pharmacological targeting of DNMT1 on CSC phenotypes. Sphere formation assay. Spheres were generated by culturing 2x10 3 PDAC cells per ml in ultralow attachment plates (Corning, NY, NY) using serum-free DMEM/F12 supplemented with B27 (1:50, Invitrogen, Waltham, MA), 20ng/ml bFGF, and 50units/ml penicillin/streptomycin for 7 days. For serial passaging, sphere cultures were first depleted for single cells and "spheres" measuring <40µm using a 40µm cell strainer. Retained spheres were dissociated into single cells, re-cultured for another 7 days.
Spheres >40μm were quantified with a CASY Cell Counter (Roche, Mannheim, Germany) (11) . Primary sphere-derived human PDAC cells were treated with Zebularine (75µM) or Decitabine (50µM) for 7days.
The drugs were re-administered every other day to the cell suspension. (12) . Probes were considered to be differentially methylated if the resulting adjusted P-value was <0.05. The Benjamini-Hochberg method was used to adjust the P-values and ensure that the false discovery rate was <0.05. The genomic region of the probes from the array were assigned according to their position relative to the transcript information obtained from the R/Bioconductor package FDb.InfiniumMethylation.hg19 (R package version 2.9.2). The CGI locations used in the analyses were obtained from the R/Bioconductor package FDb.InfiniumMethylation.hg19 (R package version 1.0.1). The definition of CGI was done as described previously (13) .
Statistical analysis.
Results for continuous variables are presented as means ± SEM unless stated otherwise and significance was determined using the Mann-Whitney U test. All analyses were performed using SPSS 22.0 (SPSS, Chicago, IL). Significance was considered at p<0.05.
Additional experimental details can be found in the Supplementary Materials and Methods.
RESULTS
Pancreatic CSCs bear higher DNA methylation levels. We first performed genome-wide comprehensive methylation profiling using the 450K Illumina bead array (14) in order to gain insight into putative DNA methylation differences between CSCs and non-CSCs. CSCs can be separated from the tumor bulk population by several methods (11); however, we recently showed that PDAC CSCs can also be efficiently isolated using autofluorescence (an accumulation of riboflavin in ATP-dependent transporter ABCG2-coated vesicles exclusively found in CSCs) (15) . Using this CSC inherent marker, we separated CSCs from non-CSCs by FACSorting ( Figure 1A ) (15) , and the efficient enrichment for CSCs was validated by increased expression of pluripotency-associated genes in autofluorescent-positive (Fluo+) CSCs versus Fluo-cells (Figure S1A/B) .
As the vast intratumoral heterogeneity in PDAC might obscure distinct methylation profiles between CSCs and non-CSCs within each contained subclone we did not only use cells derived from a heterogeneous primary pancreatic tumor (PDAC-185), but also analyzed a liver metastasis (PDAC-A6L), and a single cell-derived (SCD) tumor that was generated using a single CSC isolated from the primary tumor (PDAC-185 SCD) (Figure S1C/D) . We reasoned that the CSC heterogeneity should be highest in the primary tumor, less in the metastatic tumor and homogenous in the CSCs isolated from the SCD tumor. DNA methylation levels were compared between CSCs and non-CSCs for each individual tumor, which revealed a slight, but significant increase in DNA methylation in the Fluo+ CSC compartment, regardless of the heterogeneity or polyclonality of the CSC populations present ( Figure 1B) . These data suggest consistent differences in the methylation profile despite considerable intratumoral heterogeneity.
Furthermore, we looked at differentially methylated probes (hyper-or hypomethylation) in CSCs and found that their distribution was not universal. Hypermethylation was mostly located in non-CGI (Odds ratio[OD]=1.43) and intergenic regions (OR=1.17) and hypomethylation was mostly found in CGI (OR=1.80) and promoter regions (OR=1.43) (Figure 1C) , indicating that the hypermethylation phenotype observed in the pancreatic CSC population is largely a result of methylation of regions that are outside of traditional CGI. To further confirm this observation, we measured the levels of the DNA methylation mark 5-methylcytosine (5mC) using the MethylFlash Methylated DNA Kit or by manual dotblot analysis and show that regardless of the method used to isolate CSCs (sphere vs adherent, Fluo+ vs Fluo-, or CD133+ vs CD133-), the CSC population exhibited consistently higher levels of 5mC, indicating that cytosine was methylated to 5-methylcytosine by DNMTs, which is in line with our Illumina Array data (Figures 1D & S2A) . (Figures 2A, 2C &   S2B ). Western blot analysis confirmed higher DNMT1 protein expression in CSCs vs non-CSCs ( Figure   2B-D) . Based on the above data, we reasoned that DNMT1 overexpression plays a decisive role in preserving the stemness state of CSCs via maintaining their distinct methylation state (16) . While Zebularine expectedly showed minor or no effect on DNMT1 mRNA levels ( Figure S3D ), we observed a consistent inhibition of DNMT1 at the protein level ( Figure 3A) and a marked reduction in CD133 mRNA and surface protein levels ( Figure 3B) , suggesting preferential targeting of CSCs. A similar reduction was observed when we sorted cells for autofluorescence to identify CSCs (Figure S3E) .
At the functional level Zebularine reduced both CSC self-renewal in vitro ( Figure 3C ) and the expression of pluripotency-associated genes ( Figure 3D ). To further corroborate that pharmacological inhibition of DNMT1 is suitable for targeting pancreatic CSCs, we used another DNMT inhibitor, Decitabine (DAC).
Indeed, non-toxic levels of DAC ( Figure S4A ) decreased DNMT1 protein levels ( Figure S4B) and subsequently reduced the self-renewal capacity of CSCs in three different PDAC cultures ( Figure S4C) . Figure 3B ), but by comparing ratios between the CD133-and the CD133+ cell populations, we found that the decrease in CD133+ CSCs was followed by an increase in their CD133-negative non-CSC counterparts, suggesting that Zebularine treatment potentially induced the "differentiation" of CSCs to non-CSC ( Figure 5C ). This result was confirmed by assessing the cell surface levels of pan-Cytokeratin and E-cadherin (Figures 5D-E and S5A-B) as markers of more differentiated PDAC cells (6) . Higher expression of Pan-Cytokeratin and E-Cadherin could also be observed following DAC treatment ( Figure S4E ) and DNMT1 knockout ( Figure S5C ).
Together, our data suggest a quiescence inhibiting and differentiation promoting effect of DNMT1 inhibition on pancreatic CSCs.
DNMT1 inhibition affects CSCs via hypomethylation of the miR-17-92 cluster.
To determine the molecular mechanism(s) responsible for the effect of Zebularine on CSCs, we analyzed putative changes in DNA methylation using the Illumina Infinium HumanMethylation450 Bead Chip. As expected, Zebularine treatment decreased DNA methylation in PDAC CSCs ( Figure 6A) . Interestingly, while methylation of many genes was changed upon treatment, others even gained methylation. Using a stringent analysis approach (fold change in β-methylation values less than 0.5 and fold change higher than 2) we found 97 and 548 genes demethylated and methylated, respectively (Tables S1 & S2) . While these genes are currently under investigation, previous work by our group indicated that miRNAs (miR) have an important role in PDAC CSCs, and thus we initially focused our analysis on modulated miR. Indeed, as shown in Table 1 , we identified several miR more methylated in CSC-enriched spheres versus non-CSC adherent cultures, and using a less stringent analysis (fold change in β-methylation values 0.8) many were subsequently hypomethylated following Zebularine treatment (Table S3) .
Among these, we identified miR-203 and -205, which have previously been implicated in promoting cellular differentiation (19) . While the expression of these miR could not be confirmed to be significantly altered by Zebularine (Figure S6A) , we did see a strong and significant increase in the expression of these two miR in DNMT1-KO cells ( Figure S6B) . Next, we focused our attention on the miR-17HG (miR-17-92 cluster host gene) as a potentially methylation-regulated miR as Zebularine treatment phenocopied previous data from our laboratory related to the miR-17-92 cluster in CSCs (20) .
We previously showed that suppression of this cluster was necessary for the maintenance of CSC phenotypes and artificial overexpression of miR17-92 members forces quiescent CSCs into an active cell cycle state (20) . Likewise, previous reports have observed a CpG island in close proximity of the miR-17-92 promoter (21) . Encouraged by these findings, we further investigate whether hypermethylation of this CpG island could be responsible for the apparent suppression of this important miR cluster in CSCenriched spheres (20) . Indeed, analysis of our methylation array data showed that CpG sites in close proximity of the miR-17-92 cluster were hypomethylated upon Zebularine treatment (Table S3) . Using an independent set of CSC-enriched samples from various PDAC tumors, we observed a consistent and notable increase in the expression of several miR-17-92 members following Zebularine treatment ( Figure   6B ), with a particular increase in miR-19a and miR-19b. Consistently, the increased expression of miR-17-92 members, in particular miR-19b, was mimicked in cells lacking DNMT1 ( Figure S6C ). Of note, miR-92a, bearing a unique seed sequence distinguishing it from the other miR-17-92 family members, was not modulated by Zebularine treatment (Ctrl vs Zeb: 1.13±0.02-fold change, n.s.). Known targets of the miR-17-92 cluster, such as P21 (CDKN1A), TGFBR2, ACVR1B (ALK4), SMAD2, and SMAD4, have also been implicated in pancreatic CSC phenotypes including self-renewal and chemoresistance (11, 20) .
We found that many of these genes were suppressed upon Zebularine treatment at both the mRNA and ( Figure 6C ) and protein levels (e.g. P21) (Figure 6D ), recapitulating our previous findings (20) , and suggesting that DNMT1 inhibition is capable of unlocking the epigenetic repression of this cluster in CSCs to reactivate repressed 'anti-CSC' miR.
It has been shown that the MYC proto-oncogene family is also involved in the transcriptional regulation of miR-17-92 (22) . MYC is generally overexpressed in PDAC, but we recently showed that MYC is actually suppressed in pancreatic CSCs (23) , which may contribute to the specific reduced expression of the miR-17-92 cluster in these cells. Indeed, our methylation array data indicated that CpG 
DISCUSSION
Recent advances in our understanding of CSC epigenetics provide important insights into how these cells acquire their specific stem-like characteristics, and at the same time sheds light on how CSCs can be successfully targeted using epigenetic-modifying agents (24) . Our data demonstrate that pancreatic 
Zagorac et al. -DNMT inhibition reprograms pancreatic cancer stem cells 12 pancreatic CSCs using the DNMT1 inhibitors Zebularine and Decitabine markedly reduced their CSC functions and properties, an effect that was regulated via DNMT1-mediated demethylation of the miR-17-92 cluster promoter. These data are in line with reports for other cancers where DNMT1 was also found to be essential for the maintenance of stem cells (27, 28) , but we now also provide a mechanistic link in the context of PDAC by demonstrating the modulation of a crucial miR cluster.
Epigenetic modifications are able to alter gene expression and have been shown to play a crucial role in stem cell function and maintenance (27, 29) . As CSCs and their more differentiated progenies share the same genetic background, epigenetic changes should account for the striking functional differences between CSCs and their non-tumorigenic progenies. Specifically, we recently demonstrated that even a single CSC could give rise to a tumor that recapitulated the functional heterogeneity of the original parental tumor at the pathological, biological and genetic levels (15) . Thus, epigenetics and not genetics must be the underlying drivers of this intraclonal heterogeneity, which is indeed supported by our present finding that the genome of CSCs is hypermethylated compared to non-CSCs. Strikingly, DNA hypermethylation could not only be found in single-CSC-derived tumors that lack intratumoral heterogeneity, but also in tumors derived from metastatic lesions and even highly heterogeneous primary tumors. This finding supports the notion that hypermethylation is a consistent and robust differential factor between pancreatic CSCs and non-CSCs. At the DNA level, this hypermethylation phenotype was restricted to regions outside traditional CpG islands, specifically non-CpG islands and intergenic regions.
In general, it has been shown that cancer cells exhibit hypomethylation of intergenic regions (30) , which consequently could contribute to activation of transposable elements and genome instability. On the other hand, promoter regions of many CpG islands of tumor suppressor genes become hypermethylated resulting in their loss-of-function (31). Fortunately, using genome-scale methylation-screening approaches we have learned that a fraction of normally methylated CpG islands become hypomethylated and transcriptionally active in cancer cells (32) . Moreover, some CpG islands located within the 3′ ends of genes (33) miR-9, both well-known tumor-suppressors, were found to be suppressed in several human cancers (38) due to aberrant DNA methylation of their promoters. Thus, we sought to focus our investigation on miR genes and to identify specific CpG sites located in the proximity of various miR promoter regions in which Zebularine-mediated hypomethylation re-activated genes that were originally silenced in CSCs.
We observed that the miR-17-92 cluster (comprised of six members -miR17, 18a, 19a, 19b, 20a and 92a) was hypermethylated in CSCs vs non-CSCs ( Table 1 ). This finding is in line with recent studies from our laboratory showing that the miR-17-92 cluster is consistently downregulated in pancreatic CSCs (20) . In this study we showed that gain-of-function, using forced overexpression of miR-17-92, reduced CSC selfrenewal capacity, in vivo tumorigenicity and chemoresistance. On the other hand, downregulation of this cluster (i.e. inhibition of miR-17-92 using antagomiR) in more differentiated cells had the opposite effect, imparting non-CSCs with CSC-like phenotypes. This effect was mediated by suppressing multiple members of the NODAL/ACTIVIN/TGF-β1 signaling cascade as well as downstream targets, such as P21, P57, and TBX3, all of which have been shown to be crucial for maintaining the stem-like state of pancreatic CSCs (11, 20, 39) . Our data now further validate and expand upon these previous findings and provide novel insights into the epigenetic mechanism(s) controlling the suppression of the miR-17-92 cluster in CSCs. We show, using different approaches, that re-activation of the miR-17-92 cluster following DNMT1 pharmacological or genetic inhibition augments the phenotype of PDAC CSCs.
Unlike other DNMT inhibitors, Zebularine is more stable in aqueous solution and is less toxic in vitro and in vivo (40) . Continuous exposure of various cancer cell lines to Zebularine has already been shown to selectively slow tumor cell growth, highlighting its potential value as a chemotherapeutic agent.
It has previously been shown that Zebularine has anti-cancer effects in established PDAC cell lines, supposedly via induction of apoptosis and subsequent suppression of tumor growth in vivo (41); however, using primary low-passage PDAC cultures derived from equally low-passage PDX tumors we found no evidence for a direct pro-apoptotic effect. Instead, we show that Zebularine treatment forces normally slow-cycling CSCs into a more proliferative fast-cycling state, which has been previously linked to (42) . Moreover, we observed a marked promotion of CSC differentiation as determined by the loss of "stemness" markers (e.g. CD133) and a gain in the expression of differentiation markers including CYTOKERATIN and E-CADHERIN. More importantly, these phenotypes were recapitulated using not only a different DNMT inhibitor, Decitabine, but also in DNMT1-KO cells, indicating that regardless of the approach used, the loss of DNMT1 results in the same phenotypic changes: loss of "stemness" and promotion of differentiation.
We would like to highlight that we cannot exclude the possibility that other CSC inhibitory miR could be reactivated by Zebularine treatment (or DNMT1 inhibition). Indeed Table S3 shows that upon treatment with Zebularine, β methylation values of various miR genes were decreased. Based on this list and after careful review of the literature, we opted to focus on the two miR, miR-203 and miR-205, as both miR were previously described to play a role in the biology of pancreatic cancer (43, 44) . miR-203 acts as a known suppressor of stem cell pluripotent factors; therefore, reactivation of miR-203 by hypomethylation might contribute to the reduced levels of pluripotency-associated genes observed following Zebularine treatment in PDAC CSCs. Overexpression of miR-203 has also been demonstrated to induce expression of E-CADHERIN by inhibition of the E-CADHERIN repressors ZEB1/2, which correlates well with our E-CADHERIN immunofluorescence studies presented herein (45) . Thus, the prodifferentiation effect of Zebularine can also be potentially explained by Zebularine-induced hypomethylation of miR-203, which has previously been described as an epithelial differentiation factor (19) . Likewise, miR-205 is a well-known anti-cancer miR and is consistently downregulated in clinical pancreatic cancer samples including CSCs (44, 46) . miR-205 replenishment reduces the expression of the pluripotency/stem cell marker OCT3/4, the CSC marker CD44, and resensitizes cells to chemotherapy. 
